MicroPort CRM Raises $150 Million for Implantable CRM Devices

MicroPort Cardiac Rhythm Management closed a $150 million Series C financing including $20 million from Hillhouse and $47 million from MicroPort® Scientific, its parent. MicroPort CRM makes implantable pacemaker and defibrillator devices to manage cardiac rhythm disorders. In 2017, MicroPort acquired the CRM business of Italy 's Liva Nova for $190 Million. MicroPort® CRM is headquartered in Clamart, a suburb of Paris , with R&D teams in Clamart and  Shanghai . The parent, MicroPort® Scientific, is a global medical device company, headquartered in Shanghai . More details.... Stock Symbol: (HK: 00853) Share this with colleagues: // //